Forskning
Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital
E-pub ahead of print

Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Traveling health-promoting infrastructures: A meta-ethnographic analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • International Study of Inflammation in COVID-19
Vis graf over relationer

BACKGROUND: AKI commonly occurs in patients with coronavirus disease 2019 (COVID-19). Its pathogenesis is poorly understood. The urokinase receptor system is a key regulator of the intersection between inflammation, immunity, and coagulation, and soluble urokinase plasminogen activator receptor (suPAR) has been identified as an immunologic risk factor for AKI. Whether suPAR is associated with COVID-19-related AKI is unknown.

METHODS: In a multinational observational study of adult patients hospitalized for COVID-19, we measured suPAR levels in plasma samples from 352 adult patients that had been collected within 48 hours of admission. We examined the association between suPAR levels and incident in-hospital AKI.

RESULTS: Of the 352 patients (57.4% were male, 13.9% were black, and mean age was 61 years), 91 (25.9%) developed AKI during their hospitalization, of whom 25 (27.4%) required dialysis. The median suPAR level was 5.61 ng/ml. AKI incidence rose with increasing suPAR tertiles, from a 6.0% incidence in patients with suPAR <4.60 ng/ml (first tertile) to a 45.8% incidence of AKI in patients with suPAR levels >6.86 ng/ml (third tertile). None of the patients with suPAR <4.60 ng/ml required dialysis during their hospitalization. In multivariable analysis, the highest suPAR tertile was associated with a 9.15-fold increase in the odds of AKI (95% confidence interval [95% CI], 3.64 to 22.93) and a 22.86-fold increase in the odds of requiring dialysis (95% CI, 2.77 to 188.75). The association was independent of inflammatory markers and persisted across subgroups.

CONCLUSIONS: Admission suPAR levels in patients hospitalized for COVID-19 are predictive of in-hospital AKI and the need for dialysis. SuPAR may be a key component of the pathophysiology of AKI in COVID-19.

OriginalsprogEngelsk
TidsskriftJournal of the American Society of Nephrology : JASN
ISSN1046-6673
DOI
StatusE-pub ahead of print - 22 sep. 2020

Bibliografisk note

Copyright © 2020 by the American Society of Nephrology.

ID: 60897970